Eckert J, Deplazes P
Institut für Parasitologie, Universität Zürich.
Tierarztl Prax. 1996 Aug;24(4):322-9.
This review presents short information on the present status and some future perspectives of vaccination against parasitoses of domestic animals. For the control of such parasitoses in some European countries only a few vaccines are registered: Paracox and Livacox (for coccidiosis in chickens), Toxovax (for toxoplasmosis in sheep), Pirodog (for babesiosis in dogs) and Dictol (for dictyocaulosis in cattle). These are live vaccines containing attenuated parasites, except Pirodog. As a world-wide innovation in 1994 a vaccine against ixodid tick infestation (Boophilus microplus) in cattle was marketed in Australia under the trade name TickGARD which contains a recombinant protein antigen. A recombinant vaccine against Taenia ovis cysticercosis in sheep was developed in Australia/New Zealand but has not yet been registered. The development of vaccines against further parasitoses of domestic animals is a fascinating and promising field. Present research activities are focussed on molecular antigen vaccines and vector vaccines. First reports (for example regarding leishmaniosis and malaria) indicate that nucleic acid vaccines represent a new potential of development.
本综述介绍了家畜寄生虫病疫苗接种的现状及一些未来展望。在一些欧洲国家,用于控制此类寄生虫病的注册疫苗仅有几种:Paracox和Livacox(用于鸡球虫病)、Toxovax(用于绵羊弓形虫病)、Pirodog(用于犬巴贝斯虫病)和Dictol(用于牛网尾线虫病)。除Pirodog外,这些均为含有减毒寄生虫的活疫苗。1994年,一种用于牛蜱感染(微小牛蜱)的疫苗在澳大利亚上市,商品名为TickGARD,它含有重组蛋白抗原,这是一项全球创新。澳大利亚/新西兰研发了一种针对绵羊绵羊绦虫囊尾蚴病的重组疫苗,但尚未注册。开发针对家畜其他寄生虫病的疫苗是一个引人入胜且前景广阔的领域。目前的研究活动集中在分子抗原疫苗和载体疫苗上。首批报告(例如关于利什曼病和疟疾)表明核酸疫苗代表了一种新的发展潜力。